Scientists in Britain have developed a drug which could represent a major breakthrough in treatment for people with Alzheimer's disease.
The drug, Rember, targets the build-up of tau protein tangles which form inside the brain nerve cells of people with Alzheimer's. These tangles destroy nerve cells linked to memory, causing forgetfulness.
Alzheimers Disease
Alzheimer''s disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.
Advertisement
Professor Claude Wischik of Aberdeen University in northeast Scotland, who co-founded the company which created the drug, hailed the results as "the most significant development in the treatment of the tangles since Alois Alzheimer discovered them in 1907".
Experts have welcomed the findings but say bigger trials are needed to confirm the drug's effects and check it is safe.
An initial study into the drug's effectiveness focused on 321 people with mild and moderate Alzheimer's in Britain and Singapore.
![Know Your Nervous System]( "Know Your Nervous System")
The Central nervous system consists of the brain, the spinal cord, and the body's nerve network. This complex system is based on one kind of cell the neurons.
Those on the drug experienced an 81 percent reduction in mental decline after 50 weeks, compared to a placebo group, researchers said.
Reacting to the findings, Professor Clive Ballard, head of research at Britain's Alzheimer's Society, said: "This first modestly-sized trial in humans is potentially exciting... however, we are not there yet.
"Larger scale trials are now needed to confirm the safety of this drug and establish how far it could benefit the thousands of people living with this devastating disease."
Alzheimer's is a degenerative brain disorder which causes problems with memory and behaviour, for which there is currently no cure. It affects around 350,000 people in Britain alone.
The findings were presented at the International Conference on Alzheimer's Disease in Chicago in the United States.
Source: AFP
SRM
An initial study into the drug's effectiveness focused on 321 people with mild and moderate Alzheimer's in Britain and Singapore.
Know Your Nervous System
The Central nervous system consists of the brain, the spinal cord, and the body's nerve network. This complex system is based on one kind of cell the neurons.
Advertisement
Those on the drug experienced an 81 percent reduction in mental decline after 50 weeks, compared to a placebo group, researchers said.
Reacting to the findings, Professor Clive Ballard, head of research at Britain's Alzheimer's Society, said: "This first modestly-sized trial in humans is potentially exciting... however, we are not there yet.
"Larger scale trials are now needed to confirm the safety of this drug and establish how far it could benefit the thousands of people living with this devastating disease."
Alzheimer's is a degenerative brain disorder which causes problems with memory and behaviour, for which there is currently no cure. It affects around 350,000 people in Britain alone.
The findings were presented at the International Conference on Alzheimer's Disease in Chicago in the United States.
Source: AFP
SRM
Brilliant Human Brain - Animation
The most amazing and complex organ in the entire universe, the human brain continues to remain an enigma.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
